Luiz Carlos Junior de Alcântara, director of the Instituto Butantan, said people immunized against dengue more than 21 days ago can remain calm.
This clarification comes as Brazilian health authorities temporarily suspended the administration of the vaccine to investigate reports of adverse reactions. The suspension aims to ensure patient safety, but officials want to prevent panic among those who have already completed their initial dose.
Alcântara addressed the concerns of the public regarding the temporary halt in the rollout. He said that individuals who received the vaccine more than 21 days ago [1] do not face additional risks related to the current investigation. The timeframe suggests that the window for the specific adverse reactions being studied has passed for these individuals.
"Those who have already taken the dengue vaccine can be absolutely rested," Alcântara said.
The Instituto Butantan, based in São Paulo, is overseeing the process of investigating the reported reactions to determine the cause and frequency of the side effects. This investigative phase is a standard part of public health monitoring to maintain the integrity of the immunization campaign.
While the suspension remains in effect for new administrations, the director emphasized that the safety profile for those already immunized remains stable. He said those who have been vaccinated for more than 21 days [1] can feel tranquil about their health status.
Public health officials in Brazil continue to monitor the situation closely as they work to resume the vaccination campaign. The investigation into the adverse reactions will determine when and how the vaccine will be reintroduced to the general population.
“"Those who have already taken the dengue vaccine can be absolutely rested,"”
The temporary suspension of the dengue vaccine reflects a cautious approach to pharmacovigilance in Brazil. By specifying a 21-day window, the Instituto Butantan is attempting to isolate the risk period for adverse reactions, effectively reassuring the majority of the already-vaccinated population while they conduct a targeted safety review.
